Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 1/20 | 0.64 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.64 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.64 |
| ▸ | BCHE | P06276 | 7/20 | 0.52 |
| ▸ | ACHE | P22303 | 7/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20841683 | 0.94 | PABPC1 (0.57) | PABPC1EIF4HCTDSP1BCHEACHE | |
| SCHEMBL14314587 | 0.92 | BCHE (0.60) | PABPC1EIF4HCTDSP1BCHEACHE | |
| SCHEMBL2579375 | 0.86 | PABPC1 (0.49) | PABPC1EIF4HCTDSP1BCHEACHE | |
| SCHEMBL31397598 | 0.85 | PABPC1 (0.50) | PABPC1EIF4HCTDSP1BCHEACHE | |
| SCHEMBL17157364 | 0.83 | PABPC1 (0.69) | PABPC1EIF4HCTDSP1BCHEACHE | |
| Sulfuric Acid SCHEMBL28430154 | 0.82 | BCHE (0.46) | PABPC1EIF4HCTDSP1BCHEACHE | |
| Sulfuric Acid SCHEMBL28693598 | 0.82 | BCHE (0.46) | PABPC1EIF4HCTDSP1BCHEACHE | |
| SCHEMBL30496790 | 0.81 | ACHE (0.49) | PABPC1EIF4HCTDSP1BCHEACHE | |
| SCHEMBL4411842 | 0.81 | PABPC1 (0.62) | PABPC1EIF4HCTDSP1BCHEACHE | |
| SCHEMBL30836952 | 0.80 | PABPC1 (0.65) | PABPC1EIF4HCTDSP1BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569595-B2 | Bioprosthetic tissue preparation | EDWARDS LIFESCIENCES CORPORATION (US) | 2026-03-10 | — | — | US | claimed |
| EP-3631432-B1 | COMPOSITIONS, METHODS FOR MOLECULAR ANALYSIS | INTEGENX INC (US) | 2026-01-14 | — | — | EP | claimed |
| US-20250388896-A1 | COMPOSITION AND METHODS FOR TRANSGENE INSERTION | CELYNTRA THERAPEUTICS SA (BE) | 2025-12-25 | — | — | US | claimed |
| US-20250320406-A1 | QUANTUM DOT MATERIAL, METHOD FOR PREPARING THE SAME, AND QUANTUM DOT FILM AND BACKLIGHT MODULE USING THE SAME | FOXCONN TECH CO LTD (TW) | 2025-10-16 | — | — | US | claimed |
| EP-3880688-B1 | OLIGOSACCHARIDE PREPARATIONS AND COMPOSITIONS | DSM IP ASSETS BV (NL) | 2025-09-17 | — | — | EP | claimed |
| US-12349585-B2 | Pb-free perovskite materials for short wave IR devices | HONDA MOTOR CO., LTD. (JP) | 2025-07-01 | — | — | US | claimed |
| US-20250197817-A1 | VIRUS PURIFICATION METHOD | THE UNIVERSITY OF TOKYO (JP) | 2025-06-19 | — | — | US | claimed |
| CN-119932113-A | Suspension system for adeno-associated virus production | 生命技术公司 | 2025-05-06 | — | — | CN | claimed |
| US-12209252-B2 | Transduction buffer | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2025-01-28 | — | — | US | claimed |
| EP-4486881-A1 | COMPOSITION AND METHODS FOR TRANSGENE INSERTION | Celyntra Therapeutics SA (BE) | 2025-01-08 | — | — | EP | claimed |
| US-20070184019-A1 | Pharmaceutical composition comprising an active principal and sulphobetaine | LEK PHARMACEUTICALS D.D. (SI) | 2007-08-09 | — | — | US | claimed |
| EP-1729794-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE PRINCIPLE AND SULPHOBETAINE | LEK Pharmaceuticals D.D. (SI) | 2006-12-13 | — | — | EP | claimed |
| WO-2006059075-A1 | A METHOD FOR INCREASING THE SPECIFICITY OF ENZYMATIC DNA SYNTHESIS | BIOLINE LIMITED (GB) | 2006-06-08 | — | — | WO | claimed |
| WO-2005060989-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE PRINCIPLE AND SULPHOBETAINE | LEK PHARMACEUTICALS D.D. (CH) | 2005-07-07 | — | — | WO | claimed |
| EP-1021528-B1 | METHODS OF REFOLDING PROTEINS BY USE OF ZWITTERIONIC LOW MOLECULAR WEIGHT AGENTS | INST GENETICS LLC (US) | 2004-01-28 | — | — | EP | claimed |
| EP-0871801-B1 | ELECTROPLATING PROCESSES COMPOSITIONS AND DEPOSITS | ENTHONE OMI INC (US) | 2002-07-17 | — | — | EP | claimed |
| US-20020052026-A1 | METHODS OF REFOLDING PROTEINS | GENETICS INSTITUTE, LLC | 2002-05-02 | — | — | US | claimed |
| EP-1021528-A1 | METHODS OF REFOLDING PROTEINS BY USE OF ZWITTERIONIC LOW MOLECULAR WEIGHT AGENTS | GENETICS INSTITUTE, INC. (US) | 2000-07-26 | — | — | EP | claimed |
| WO-1999018196-A1 | METHODS OF REFOLDING PROTEINS BY USE OF ZWITTERIONIC LOW MOLECULAR WEIGHT AGENTS | GENETICS INSTITUTE, INC. (US) | 1999-04-15 | — | — | WO | claimed |
| EP-0480876-A2 | Electrodeposition of a gold alloy containing copper and zinc and its method of production | METAUX PRECIEUX SA METALOR (CH) | 1992-04-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388896-A1 | COMPOSITION AND METHODS FOR TRANSGENE INSERTION | GDA, XPA, ERCC2 | PABPC1 561/4885EIF4H 2915/4885CTDSP1 1163/4885 |
| US-12569595-B2 | Bioprosthetic tissue preparation | BCHE, LNPEP, DPEP1 | PABPC1 1229/4885EIF4H 3105/4885CTDSP1 842/4885 |
| US-20070184019-A1 | Pharmaceutical composition comprising an active principal and sulphobetaine | SCN2B, SCN1B, SPTSSB | PABPC1 2564/4885EIF4H 4292/4885CTDSP1 2040/4885 |
| US-12209252-B2 | Transduction buffer | STAT3, JAK2, CFTR | PABPC1 4322/4885EIF4H 4215/4885CTDSP1 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.